Systemic adverse events at · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in participants with adverse events ‐ systemic adverse eventsClinical… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ injection site adverse events Clinical criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to higher participants with adverse events ‐ injection site adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in dropoutsClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
Cumulative incidence of herpes zoster at least 3.2 years · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to lower cumulative incidence of herpes zoster at least 3.2 years compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ death Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ deathClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation showed no clear difference in all‐cause mortality compared with no zinc supplementation (high certainty).
1 finding from 1 review
Mortality due to all‐cause diarrhea · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation showed no clear difference in mortality due to all‐cause diarrhea compared with no zinc supplementation (moderate certainty).
1 finding from 1 review
Mortality due to LRTI · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation showed no clear difference in mortality due to LRTI compared with no zinc supplementation (moderate certainty).
1 finding from 1 review
Mortality due to malaria · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation showed no clear difference in mortality due to malaria compared with no zinc supplementation (moderate certainty).
1 finding from 1 review
Diarrhea · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation probably leads to lower incidence of all‐cause diarrhea compared with no zinc supplementation (moderate certainty).
1 finding from 1 review
Incidence of LRTI · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation showed no clear difference in incidence of LRTI compared with no zinc supplementation (high certainty).
1 finding from 1 review
Height (cm) · otherwise healthy children aged 6 months to 12 years of age
1 finding from 1 review
Participants with ≥ 1 vomiting episode · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation leads to higher participants with ≥ 1 vomiting episode compared with no zinc supplementation (high certainty).
1 finding from 1 review
Anaemia · population aged 2 years and above (Ballot 1989a (C) ‐ > 10 years, Chen 2005 (C) ‐ >3 years; Huo 2002 ‐ 11‐17 years, Longfils 2008‐ 6‐21…
It is very uncertain whether condiments/seasonings fortified with iron changes anaemia (defined as haemoglobin below WHO cut‐off for age and… compared with unfortified condiments/seasonings (very low certainty).
1 finding from 1 review
Iron deficiency (as defined by study authors, based on a biomarker of iron status) · population aged 2 years and above (Andersson 2008 ‐ 5‐18 years, Asibey‐Berko 2007 ~ 3 years, Chen Ke 2008 ‐ 2‐6 years, Haas 2014 ‐ women…
Condiments/seasonings fortified with iron plus other micronutrients may leads to lower iron deficiency (as defined by the trialists based on a biomarker of… compared with condiments/seasonings fortified with other micronutrients except iron (low certainty).
1 finding from 1 review
Ferritin (µg/L) · population aged 2 years and above (Andersson 2008 ‐ 5‐18 years, Asibey‐Berko 2007 ~ 3 years, Chen Ke 2008 ‐ 2‐6 years, Haas 2014 ‐ women…
1 finding from 1 review
Transferrin saturation · population aged 2 years and above (Andersson 2008 ‐ 5‐18 years, Asibey‐Berko 2007 ~ 3 years, Chen Ke 2008 ‐ 2‐6 years, Haas 2014 ‐ women…
1 finding from 1 review
Total iron binding capacity · population aged 2 years and above (Andersson 2008 ‐ 5‐18 years, Asibey‐Berko 2007 ~ 3 years, Chen Ke 2008 ‐ 2‐6 years, Haas 2014 ‐ women…
1 finding from 1 review
Adverse effects · population aged 2 years and above (Andersson 2008 ‐ 5‐18 years, Asibey‐Berko 2007 ~ 3 years, Chen Ke 2008 ‐ 2‐6 years, Haas 2014 ‐ women…
1 finding from 1 review
Haemoglobin (g/dL) · population aged 2 years and above (Ballot 1989a (C) ‐ > 10 years, Chen 2005 (C) ‐ >3 years; Huo 2002 ‐ 11‐17 years, Longfils 2008‐ 6‐21…
1 finding from 1 review